Machado-Joseph disease
- PMID: 7614089
Machado-Joseph disease
Abstract
Machado-Joseph disease (MJD) is a form of dominantly-inherited ataxia originally described in people of Azorean and Portuguese descent. The disorder has subsequently been identified in Japan, Brazil, Australia, and China. Average age of onset is 35 to 40. Core features include progressive ataxia, dysarthria, postural instability, nystagmus, eyelid retraction, and facial fasciculations. Dystonia is often prominent in younger patients. Three distinct phenotypes appear to reflect the clinical spectrum of a single mutant gene. Neuropathology involves afferent and efferent cerebellar systems, with preservation of cerebellar cortex and inferior olive. Spinocerebellar pathways, substantia nigra, and cranial nerve motor nuclei are involved. The disorder is due to an unstable CAG repeat on chromosome 14q32.1. A dominantly inherited ataxia (SCA-3) in families of French and German descent has also been linked to this segment of chromosome 14. The relationship between MJD and the other dominant inherited ataxias is discussed.
Similar articles
-
Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease.Ann Neurol. 1995 Jul;38(1):68-72. doi: 10.1002/ana.410380113. Ann Neurol. 1995. PMID: 7611728
-
Muscle excitability abnormalities in Machado-Joseph disease.Arch Neurol. 2008 Apr;65(4):525-9. doi: 10.1001/archneur.65.4.525. Arch Neurol. 2008. PMID: 18413477
-
Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features.Ann Neurol. 1996 Apr;39(4):490-9. doi: 10.1002/ana.410390411. Ann Neurol. 1996. PMID: 8619527
-
Dominantly inherited ataxias: lessons learned from Machado-Joseph disease/spinocerebellar ataxia type 3.Semin Neurol. 2007 Apr;27(2):133-42. doi: 10.1055/s-2007-971172. Semin Neurol. 2007. PMID: 17390258 Review.
-
[Molecular genetics of Machado-Joseph disease].Nihon Rinsho. 1996 Mar;54(3):854-60. Nihon Rinsho. 1996. PMID: 8904248 Review. Japanese.
Cited by
-
A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases.Front Mol Neurosci. 2022 Sep 14;15:974167. doi: 10.3389/fnmol.2022.974167. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36187346 Free PMC article. Review.
-
Chaperone-assisted E3 ligase CHIP: A double agent in cancer.Genes Dis. 2021 Sep 1;9(6):1521-1555. doi: 10.1016/j.gendis.2021.08.003. eCollection 2022 Nov. Genes Dis. 2021. PMID: 36157498 Free PMC article. Review.
-
Cerebellar morphometric and spectroscopic biomarkers for Machado-Joseph Disease.Acta Neuropathol Commun. 2022 Mar 19;10(1):37. doi: 10.1186/s40478-022-01329-4. Acta Neuropathol Commun. 2022. PMID: 35305685 Free PMC article.
-
Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies.Biomedicines. 2021 Oct 20;9(11):1499. doi: 10.3390/biomedicines9111499. Biomedicines. 2021. PMID: 34829728 Free PMC article. Review.
-
ULK overexpression mitigates motor deficits and neuropathology in mouse models of Machado-Joseph disease.Mol Ther. 2022 Jan 5;30(1):370-387. doi: 10.1016/j.ymthe.2021.07.012. Epub 2021 Jul 21. Mol Ther. 2022. PMID: 34298131 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources